Physician profile
David Schuster
NPI 1972009488
$2,314.17
in general payments reported to CMS, 2019-2025
19 companies · $730 in 2025
The $730 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $390 · 2024: $1,194 · 2025: $730.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,314 · Education: $0.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,313.67 |
| Education | $0.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuropace, INC. | $493.36 | 2023-2024 | |
| Abbvie INC. | $438.10 | 2023-2025 | Ubrelvy, Botox |
| Ucb, INC. | $256.20 | 2023-2025 | Briviact, Rystiggo, Nayzilam |
| Sk Life Science, INC. | $234.42 | 2023-2025 | Xcopri |
| Lilly USA, LLC | $217.53 | 2023-2025 | Emgality, Reyvow, Kisunla |
| Pfizer INC. | $210.22 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $115.10 | 2023-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Mdd US Operations, LLC | $71.72 | 2025 | Apokyn |
| Lundbeck LLC | $67.26 | 2023-2025 | Vyepti |
| Neurelis, INC. | $54.40 | 2024-2025 | Valtoco |
| Ceribell, INC. | $26.03 | 2025 | Pocket Eeg Device |
| Neuronetics, INC. | $21.46 | 2023 | Neurostar Tms Therapy System |
| Otter Pharmaceuticals, LLC | $17.15 | 2025 | Sympazan |
| Axsome Therapeutics, INC. | $16.69 | 2025 | Symbravo |
| Neurocrine Biosciences, INC. | $16.16 | 2023 | Ongentys, Ingrezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $16.00 | 2025 | Brekiya |
| Catalyst Pharmaceuticals, INC. | $15.00 | 2024 | |
| Eisai INC. | $14.45 | 2023 | |
| Aucta Pharmaceuticals, INC. | $12.92 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schuster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.